What's Happening?
Phlow Corp., a Richmond, Virginia-based pharmaceutical company, has appointed Dawn Von Rohr as its new Chief Operating Officer. Von Rohr will oversee the company's operations and strategic growth initiatives, focusing on expanding domestic pharmaceutical manufacturing.
Phlow aims to strengthen the U.S. supply chain for medicines and active pharmaceutical ingredients (APIs) by scaling its advanced manufacturing capabilities. The appointment is part of Phlow's efforts to support the U.S. Government's essential medicine programs and biopharma customers' reshoring initiatives. Von Rohr brings over 30 years of experience in pharmaceutical manufacturing and global supply chain operations, having held senior roles at Pace Life Sciences and Curia Global.
Why It's Important?
Phlow's focus on enhancing domestic pharmaceutical manufacturing is critical for improving the resilience and security of the U.S. medicine supply chain. The COVID-19 pandemic highlighted vulnerabilities in global supply chains, prompting a push for more localized production of essential medicines. By investing in advanced manufacturing infrastructure, Phlow aims to reduce dependency on foreign suppliers and ensure a stable supply of high-quality medicines. This initiative supports national preparedness and aligns with broader efforts to bolster U.S. manufacturing capabilities.
What's Next?
Von Rohr's leadership is expected to drive Phlow's strategic initiatives, including the expansion of its manufacturing infrastructure and the development of the Strategic Active Pharmaceutical Ingredient Reserve (SAPIR) program. As the company scales its operations, it will likely seek partnerships with government and industry stakeholders to enhance supply chain resilience. The success of these efforts could influence future policies and investments in domestic pharmaceutical manufacturing.
